Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Qualitative Analysis of the Role of Metabolites in Inhibitory Drug−Drug Interactions: Literature Evaluation Based on the Metabolism and Transport Drug Interaction Database

View Author Information
Department of Pharmaceutics, University of Washington, P.O. Box 357610, Seattle, Washington 98195
* To whom correspondence should be addressed. Tel: 206-543-2517. Fax: 206-543-320. E-mail: [email protected]
Cite this: Chem. Res. Toxicol. 2009, 22, 2, 294–298
Publication Date (Web):February 16, 2009
Copyright © 2009 American Chemical Society

    Article Views





    Other access options


    Abstract Image

    Guidance from the Food and Drug Administration on drug interaction studies does not include a specific section on contributions of metabolites to observed inhibitory drug−drug interactions, and the quantitative role of drug metabolites in inhibitory drug−drug interactions is not presently known. The current work was undertaken to evaluate what fraction of inhibitors of common drug-metabolizing enzymes [cytochrome P450 (P450) 1A2, 2E1, 2D6, 2C9, 2C19, 2C8, 2B6, and 3A4] have circulating metabolites that may contribute to observed in vivo interactions. A literature analysis was conducted using the Metabolism and Transport Drug Interaction Database to identify all precipitants (i.e., inhibitors) that cause more than a 20% increase in the area under the plasma concentration−time curve (AUC) of marker substrates. The database, PubMed, and product labels were then used to determine whether circulating metabolites were present after administration of these inhibitors. Of the total of 129 inhibitors identified, 106 were confirmed to have metabolites that circulate in plasma. An additional 14 inhibitors were identified that are extensively metabolized but whose metabolites either have not been identified or have not been investigated. Hence, only 7% of the inhibitors did not have circulating metabolites. Of the 21 potent inhibitors (≥5-fold increase in AUC) currently known, 17 had circulating metabolites, and the remaining four were all extensively metabolized. On the basis of available in vitro data, 24 of all of the inhibitors were mechanism-based inactivators of P450 enzymes, while 105 were characterized as reversible inhibitors. In vitro evaluation of inhibition potential was conducted for only 32% of the circulating metabolites of the inhibitors. In conclusion, circulating metabolites are often present with inhibitors of P450 enzymes, suggesting a need for increased efforts to characterize the inhibitory potency of metabolites of candidate drugs and for newer models for in vitro to in vivo extrapolations.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 48 publications.

    1. Edurne Nuin, M. Consuelo Jiménez, Germán Sastre, Inmaculada Andreu, and Miguel A. Miranda . Drug–Drug Interactions within Protein Cavities Probed by Triplet–Triplet Energy Transfer. The Journal of Physical Chemistry Letters 2013, 4 (10) , 1603-1607.
    2. Nina Isoherranen, Justin D. Lutz, Sophie P. Chung, Houda Hachad, Rene H. Levy, and Isabelle Ragueneau-Majlessi . Importance of Multi-P450 Inhibition in Drug–Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data. Chemical Research in Toxicology 2012, 25 (11) , 2285-2300.
    3. Makoto Kataoka, Shota Ohshiro, Keiko Minami, Tsubasa Hasegawa, Haruki Higashino, Toshihide Takagi, Kazutaka Togashi, Kuninori Mutaguchi, Shinji Yamashita. Contribution analysis of metabolic tissues on systemic exposure of an active metabolite after oral administration of verapamil using a stable isotope-labeled compound. Drug Metabolism and Pharmacokinetics 2023, 51 , 100514.
    4. Yuhong Yang, Jian Yang, Hongling Wang, Yusong Jin, Jing Liu, Ranran Jia, Zhuo Wang, Zongli Kang. Analysis of primary metabolites of Morchella fruit bodies and mycelium based on widely targeted metabolomics. Archives of Microbiology 2022, 204 (1)
    5. Shuaibing Liu, Lei Hou, Cai Li, Yibo Zhao, Xia Yao, Xiaojian Zhang, Xin Tian. Contributions of UDP-Glucuronosyltransferases to Human Hepatic and Intestinal Metabolism of Ticagrelor and Inhibition of UGTs and Cytochrome P450 Enzymes by Ticagrelor and its Glucuronidated Metabolite. Frontiers in Pharmacology 2021, 12
    6. Claire Steinbronn, Xinning Yang, Jingjing Yu, Hristina Dimova, Shiew‐Mei Huang, Isabelle Ragueneau‐Majlessi, Nina Isoherranen. Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018. Clinical Pharmacology & Therapeutics 2021, 110 (2) , 452-463.
    7. Blessy George, Xia Wen, Edgar A. Jaimes, Melanie S. Joy, Lauren M. Aleksunes. In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs. International Journal of Molecular Sciences 2021, 22 (12) , 6439.
    8. Weibin Xiao, Zhirong Deng, Chongfa Lai, Haoyang Lu, Mutu Huang, Yuguan Wen, Lei Shi. Inhibitory effect of ketoconazole, quinidine and 1-aminobenzotriazole on pharmacokinetics of l- tetrahydropalmatine and its metabolite in rats. Xenobiotica 2021, 51 (4) , 447-454.
    9. Nina Isoherranen, Robert S. Foti. In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. 2020, 273-309.
    10. Kenta Yoshida, Kazuya Maeda, Akihiko Konagaya, Hiroyuki Kusuhara. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. Drug Metabolism and Disposition 2018, 46 (11) , 1805-1816.
    11. Caifu Xue, Xunjie Zhang, Weimin Cai. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Pharmaceutics 2018, 10 (1) , 1.
    12. R. Scott Obach, Jian Lin, Emi Kimoto, Sridhar Duvvuri, Timothy Nicholas, Eugene P. Kadar, Larry M. Tremaine, Aarti Sawant-Basak. Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio. Drug Metabolism and Disposition 2018, 46 (2) , 89-99.
    13. Momir Mikov, Maja Đanić, Nebojša Pavlović, Bojan Stanimirov, Svetlana Goločorbin-Kon, Karmen Stankov, Hani Al-Salami. The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics 2017, 42 (6) , 881-890.
    14. Xin Li, Changyong Yang, Hong Wan, Ge Zhang, Jun Feng, Lei Zhang, Xiaoyan Chen, Dafang Zhong, Liguang Lou, Weikang Tao, Lianshan Zhang. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. European Journal of Pharmaceutical Sciences 2017, 110 , 51-61.
    15. Tsubasa Hasegawa, Satomi Nakanishi, Keiko Minami, Haruki Higashino, Makoto Kataoka, Yoshihisa Shitara, Shinji Yamashita. Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction. Drug Metabolism and Pharmacokinetics 2017, 32 (1) , 69-76.
    16. Ken Grime, Rikard Pehrson, Pär Nordell, Michael Gillen, Wolfgang Kühn, Timothy Mant, Marie Brännström, Petter Svanberg, Barry Jones, Clive Brealey. An S‐warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N‐deacetylated amino acid metabolite as the primary perpetrator. British Journal of Clinical Pharmacology 2017, 83 (2) , 381-392.
    17. I. J. Martin, S. E. Hill, J. A. Baker, S. V. Deshmukh, E. F. Mulrooney. A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose. Drug Metabolism and Disposition 2016, 44 (8) , 1435-1440.
    18. Manthena V. S. Varma, Jian Lin, Yi-an Bi, Emi Kimoto, A. David Rodrigues. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1- O - β -Glucuronide. Drug Metabolism and Disposition 2015, 43 (7) , 1108-1118.
    19. Dan-dan Tian, Wei-wei Jia, Xin-wei Liu, Dan-dan Wang, Jun-hua Liu, Jia-jia Dong, Li Li, Fei-fei Du, Fang Xu, Feng-qing Wang, Yan Sun, Yu-xing Huang, Mei-juan Li, Li-hong Hu, Yan Zhu, Xiu-mei Gao, Chuan Li, Jun-ling Yang. Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen). Acta Pharmacologica Sinica 2015, 36 (5) , 627-643.
    20. Hongbin Yu, Suresh K. Balani, Weichao Chen, Donghui Cui, Ling He, W. Griffith Humphreys, Jialin Mao, W. George Lai, Anthony J. Lee, Heng-Keang Lim, Christopher MacLauchlin, Chandra Prakash, Sekhar Surapaneni, Susanna Tse, Alana Upthagrove, Robert L. Walsky, Bo Wen, Zhaopie Zeng. Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group. Drug Metabolism and Disposition 2015, 43 (4) , 620-630.
    21. Manthena V. Varma, K. Sandy Pang, Nina Isoherranen, Ping Zhao. Dealing with the complex drug–drug interactions: Towards mechanistic models. Biopharmaceutics & Drug Disposition 2015, 36 (2) , 71-92.
    22. Johanna Weiss, Sybille Baumann, Dirk Theile, Walter Emil Haefeli. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan. Pulmonary Pharmacology & Therapeutics 2015, 30 , 80-86.
    23. Yuan Chen, Jialin Mao, Cornelis E. C. A. Hop. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone. Drug Metabolism and Disposition 2015, 43 (2) , 182-189.
    24. Jiangjuan Shao, Jianwei Chen, Tingting Li, Xiaoli Zhao. Spectroscopic and Molecular Docking Studies of the in Vitro Interaction between Puerarin and Cytochrome P450. Molecules 2014, 19 (4) , 4760-4769.
    25. Su-Er W Huskey, Wenkui Li, James B Mangold, Jimmy Flarakos. An Industry Perspective on Tiered Approach to The Investigation of Metabolites in Drug Development. Bioanalysis 2014, 6 (5) , 617-628.
    26. Ninad Ramesh Varkhede, Shalu Jhajra, Deepak Suresh Ahire, Saranjit Singh. Metabolite identification studies on amiodarone in in vitro (rat liver microsomes, rat and human liver S9 fractions) and in vivo (rat feces, urine, plasma) matrices by using liquid chromatography with high‐resolution mass spectrometry and multiple‐stage mass spectrometry: Characterization of the diquinone metabolite supposedly responsible for the drug's hepatotoxicity. Rapid Communications in Mass Spectrometry 2014, 28 (4) , 311-331.
    27. Ernesto Callegari, Amit S. Kalgutkar, Louis Leung, R. Scott Obach, David R. Plowchalk, Susanna Tse. Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development. Drug Metabolism and Disposition 2013, 41 (12) , 2047-2055.
    28. Justin D. Lutz, Brooke M. VandenBrink, Katipudi N. Babu, Wendel L. Nelson, Kent L. Kunze, Nina Isoherranen. Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems. Drug Metabolism and Disposition 2013, 41 (12) , 2056-2065.
    29. Susan S. Schiffman, Kristina I. Rother. Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues. Journal of Toxicology and Environmental Health, Part B 2013, 16 (7) , 399-451.
    30. Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis, Nina Isoherranen. Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions. Drug Metabolism and Disposition 2013, 41 (7) , 1414-1424.
    31. Cho-Ming Loi, Dennis A. Smith, Deepak Dalvie. Which Metabolites Circulate?. Drug Metabolism and Disposition 2013, 41 (5) , 933-951.
    32. Hongbin Yu, Donald Tweedie. A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency. Drug Metabolism and Disposition 2013, 41 (3) , 536-540.
    33. Robert S. Foti, Josh T. Pearson, Simon L. Wong, Julie A. Zalikowski, Michael D. Boudreaux, Samantha P. Prokop, John A. Davis, Christopher Banfield, Maurice G. Emery, Dan A. Rock, Jan L. Wahlstrom, Larry C. Wienkers, Benny M. Amore. Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid and Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cells Receptors. Drug Metabolism and Disposition 2012, 40 (12) , 2239-2249.
    34. Tewes Tralau, Andreas Luch. “Drugs on oxygen”: an update and perspective on the role of cytochrome P450 testing in pharmacology. Expert Opinion on Drug Metabolism & Toxicology 2012, 8 (11) , 1357-1362.
    35. Murali Subramanian, Timothy S. Tracy. Drug–Drug Interactions 1: Inhibition. 2012, 1-24.
    36. Yasushi Fujioka, Kent L. Kunze, Nina Isoherranen. Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions. Drug Metabolism and Disposition 2012, 40 (9) , 1653-1657.
    37. J Honkalammi, M Niemi, P J Neuvonen, J T Backman. Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses. Clinical Pharmacology & Therapeutics 2012, 91 (5) , 846-855.
    38. Justin D Lutz, Nina Isoherranen. In vitro -to- in vivo predictions of drug–drug interactions involving multiple reversible inhibitors. Expert Opinion on Drug Metabolism & Toxicology 2012, 8 (4) , 449-466.
    39. C K Yeung, Y Fujioka, H Hachad, R H Levy, N Isoherranen. Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency. Clinical Pharmacology & Therapeutics 2011, 89 (1) , 105-113.
    40. Eleanor J. Guest, Karen Rowland‐Yeo, Amin Rostami‐Hodjegan, Geoffrey T. Tucker, J. Brian Houston, Aleksandra Galetin. Assessment of algorithms for predicting drug–drug interactions via inhibition mechanisms: comparison of dynamic and static models. British Journal of Clinical Pharmacology 2011, 71 (1) , 72-87.
    41. K. Sandy Pang, Matthew R. Durk. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. Journal of Pharmacokinetics and Pharmacodynamics 2010, 37 (6) , 591-615.
    42. J. Greg Slatter. Safety Testing of Drug Metabolites: Mist Guidance Impact on the Practice of Industrial Drug Metabolism. 2010, 295-312.
    43. I Templeton, C-C Peng, K E Thummel, C Davis, K L Kunze, N Isoherranen. Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data. Clinical Pharmacology & Therapeutics 2010, 88 (4) , 499-505.
    44. Kiyomi Ito, Yuichi Sugiyama. Use of clearance concepts and modeling techniques in the prediction of metabolic drug–drug interactions. Trends in Pharmacological Sciences 2010, 31 (8) , 351-355.
    45. Kuresh A. Youdim, Kenneth C. Saunders. A review of LC–MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s. Journal of Chromatography B 2010, 878 (17-18) , 1326-1336.
    46. . Suggested Further Reading. 2010, 319-327.
    47. Frédéric Y. Bois. Physiologically Based Modelling and Prediction of Drug Interactions. Basic & Clinical Pharmacology & Toxicology 2010, 106 (3) , 154-161.
    48. Bernard P. Murray. Chapter 26 Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450. 2009, 535-553.